Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 42 Significant growth opportunities fuelled by strong pipeline across all four strategic focus areas PHASE 1 NN1436 NN9023 1 LAI287 OG2023SC NN9838 Amylin analogue PHASE 2 Anti-IL-21 and liraglutide Concizumab Somapacitan - QW GHD1 NN9747 PYY 1562 analogue Semaglutide NASH NN9277 GG-co-agonist NN9423 Tri-agonist 1706 NN9775 PYY 1875 analogue NN7170 Sc N8-GP Diabetes Obesity Haemophilia PHASE 3 SUBMITTED APPROVED Oral semaglutide Semaglutide obesity N8-GP Long-acting rFVIII Levemir® Somapacitan - QW AGHD2 Growth disorders Other serious chronic diseases 1 Study conducted in growth hormone disorders; 2 Study conducted in adult growth hormone disorder; 3 RebinynⓇ is the brand name in the USA and Refixia® in the EU QW: Once-weekly; GG: Glucagon GLP-1; Sc: Subcutaneous; QD: Once-daily changing diabetes® NovoRapidⓇ NovoMix® Tresiba® RyzodegⓇ XultophyⓇ VictozaⓇ FiaspⓇ OzempicⓇ SaxendaⓇ NovoSevenⓇ NovoEight® NovoThirteenⓇ RebinynⓇ/RefixiaⓇ3 Norditropin® novo nordisk

View entire presentation